BRAF and leukemia: Nevertheless, it is important to note that CIMP is not a specific phenotype of IDH1/IDH2 oncogenic variants but could also be detected in the presence of mutations in other regulators of the IDH-epigenetic pathway, such as TET2 mutations in leukemia [20] and the BRAF p.V600E mutation in colorectal cancer [21,22].